Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 6/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6543385 | 0.81 | CHRNA7 (0.48) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL6543734 | 0.79 | CHRNA7 (0.67) | CHRNA7HTR3AKCNH2CHRNB2CHRNA4 | |
| SCHEMBL5115004 | 0.74 | CHRNA7 (0.62) | CHRNA7HTR3AKCNH2CHRNB2CHRNA4 | |
| SCHEMBL22164842 | 0.72 | CHRNA7 (0.48) | CHRNA7HTR3AKCNH2CHRNA1CHRNB2 | |
| SCHEMBL5107855 | 0.71 | CHRNA7 (0.57) | CHRNA7HTR3ACHRNB2CHRNA4 | |
| SCHEMBL5115976 | 0.71 | CHRNA7 (0.57) | CHRNA7HTR3ACHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL5122590 | 0.70 | CHRNA7 (0.60) | CHRNA7HTR3ACHRNB2CHRNA4 | |
| SCHEMBL6544013 | 0.70 | CHRNA7 (0.56) | CHRNA7HTR3AKCNH2 | |
| SCHEMBL26964265 | 0.67 | KDM4E (0.67) | KDM4E | |
| SCHEMBL22171115 | 0.66 | CHRNA7 (0.51) | CHRNA7HTR3AKCNH2CHRNA1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835730-B2 | Nicotinic receptor agonists | SANOFI-SYNTHELABO (FR) | 2004-12-28 | — | — | US | disclosed |
| EP-1254139-B1 | 4-HETEROARYL-1,4-DIAZABICYCLO 3.2.2]NONANE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SYNTHELABO (FR) | 2003-08-20 | — | — | EP | disclosed |
| US-20030119840-A1 | 4-Heteroparyl-1,4-diazabicyclo[3.2.2]nonane, preparation and therapeutic use thereof | SANOFI (FR) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119840-A1 | 4-Heteroparyl-1,4-diazabicyclo[3.2.2]nonane, preparation and therapeutic use thereof | CYC1, CBR1, CNR1 | CHRNA7 387/4885KDM4E 3656/4885HTR3A 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.